Brought to you by 
Denali, Washington U. collaborate on ApoE antibodies for Alzheimer’s disease
20 Sep 2017
Executive Summary
Denali Therapeutics Inc. and Washington University School of Medicine will collaborate to develop antibodies targeting apolipoprotein E (ApoE), a protein known to cause neurodegeneration.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Denali, Washington U. collaborate on ApoE antibodies for Alzheimer’s disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice